KINGSWAY Corp quarterly report, Q3 FY2023

Kingsway Financial Services Inc. — Q3 2023 Form 10-Q

Reporting period: Three and nine months ended September 30, 2023. Unaudited; amounts below are in U.S. dollars. Kingsway is a holding company operating in extended warranties and business services through its Extended Warranty and Kingsway Search Xcelerator segments. Leased Real Estate is reported as discontinued operations.

Financial performance

MetricQ3 2023Q3 2022Nine months 2023Nine months 2022
Revenue$24.8m$22.4m$77.4m$68.4m
Operating income (loss)($0.2m)($4.3m)$1.1m($3.5m)
Continuing operations income (loss), after tax($0.8m)$38.9m$25.2m$31.8m
Net income (loss)($0.7m)$37.3m$25.5m$32.4m
Net income (loss) attributable to common shareholders($1.0m)$38.3m$25.3m$32.8m
Net cash from (used in) operating activitiesNot provided for quarterNot provided for quarter($9.1m)$9.3m
  • Revenue rose about 11% in Q3 and 13% for the nine-month period. Nine-month segment operating income, a company-defined non-GAAP measure, was $8.8m versus $9.5m.
  • Q3 operating expenses were $25.0m against $24.8m of revenue, producing a $0.2m operating loss. Claims authorized, commissions and cost of services sold increased year over year in the quarter.
  • Extended Warranty revenue was $17.3m in Q3, down 7% year over year; segment operating income was $1.8m versus $2.5m. Kingsway Search Xcelerator revenue was $7.5m versus $3.8m and segment operating income was $1.0m versus $0.7m, reflecting acquisitions and Ravix growth.
  • Interest expense was $1.1m in Q3 and $5.1m year to date, compared with $2.1m and $5.2m, respectively, in 2022. Basic and diluted Q3 net loss per share was $0.04; nine-month basic and diluted earnings per share were $1.00 and $0.97.

Financial position, debt and liquidity

  • At September 30, 2023, total assets were $198.0m, total liabilities $169.9m and shareholders’ equity $28.1m. At December 31, 2022, these were $285.7m, $263.5m and $16.1m, respectively.
  • Cash and cash equivalents were $20.2m and restricted cash $9.1m, totaling $29.3m, compared with $77.2m combined at year-end 2022. Management reported holding-company cash of $12.4m, down from $48.9m.
  • Debt carrying value was $40.9m, down from $102.1m: bank loans were $28.3m versus $34.3m, and subordinated debt was $12.6m versus $67.8m. The company repurchased five trust preferred debt instruments for $56.5m, removing $75.5m of principal and $23.0m of deferred interest and recognizing a $31.6m extinguishment gain. One $15.0m-principal instrument remained.
  • Nine-month cash used in continuing operations was $9.6m; investing activities provided $16.7m and financing activities used $55.1m. Financing outflows included the debt repurchase, bank-loan repayments, and distributions; warrant exercises provided $16.7m.
  • Management said existing cash, investments and anticipated operating cash flows were expected to cover working capital and operating needs for the next 12 months. A further $10m delayed-draw facility was available but undrawn at September 30. A substantial portion of warranty-related cash is restricted for future claims.

Changes, outlook and notable items

  • Management attributed pressure on auto warranty businesses to consumer payment constraints, elevated used-car prices, and inflation in parts and labor that raised claims costs. Trinity also experienced lower service activity amid mild weather and delays in parts and installations. Management said Q3 claims were below Q2 2023, though above the prior-year quarter.
  • Lower Extended Warranty results were partly offset by growth in Search Xcelerator, including CSuite and Secure Nursing Service (SNS), acquired in November 2022. Kingsway acquired software company Systems Products International (SPI) for $2.8m in September 2023; its purchase-price allocation remained provisional.
  • Reported earnings are affected by significant nonrecurring and fair-value items. Q3 2022 included a $37.9m subsidiary-disposal gain and a $13.5m gain on trust preferred debt repurchase options. Nine-month 2023 results included the $31.6m debt-extinguishment gain and $3.4m of equity-investment gains, including $3.3m related to Limbach shares sold in Q3.
  • Operating cash flow included payments for management fees, the Mendota indemnity and deferred trust-preferred interest. Kingsway says it has no remaining Mendota open-claims exposure. The VA Lafayette real estate disposal group remained held for sale, with $19.5m of assets and $16.2m of liabilities.
  • Subsequent to quarter-end, Kingsway announced an agreement to acquire 95% of National Institute of Clinical Research for approximately $7.9m, expected to close in Q1 2024, and acquired Digital Diagnostics Imaging for $11.0m, funded with $5.4m cash and $5.6m debt.
  • No specific financial guidance was provided. The filing warns that actual results may differ from forward-looking statements and identifies macroeconomic conditions among factors that could affect management’s liquidity assessment.
  • Disclosure controls were deemed ineffective because of an unremediated material weakness involving accounting for and disclosure of certain complex, nonrecurring transactions, particularly application of revenue-recognition standard ASU 2014-09. Management described remediation work as ongoing.

Important facts for investors to verify

  • Whether underlying segment profitability and claims trends improve, separating operating performance from debt, investment and disposal gains.
  • Cash availability at the holding company, restricted warranty funds, operating cash conversion, and covenant limits on subsidiary distributions.
  • Debt repayment capacity, interest rates on bank loans, and the terms and covenants of new financing, including post-quarter acquisitions.
  • Final SPI purchase accounting and the performance, funding and integration of SPI, NICR and Digital Diagnostics Imaging.
  • Progress toward remediating the material weakness and the potential outcomes of the Aegis indemnity matter; the filing says potential exposure was not reasonably determinable and records no liability.
  • Execution and funding of the VA Lafayette sale, and the impact of its held-for-sale assets and liabilities.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.